Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Lutetium-177 Vipivotide Tetraxetan

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis' Pluvicto to Slow Prostate Cancer in Earlier Setting
    Novartis' Pluvicto to Slow Prostate Cancer in Earlier Setting

    03 Jun 2025

    // REUTERS

    https://www.reuters.com/sustainability/boards-policy-regulation/novartis-pluvicto-shown-slow-prostate-cancer-earlier-setting-2025-06-02/

    REUTERS
    03 Jun 2025
    Share Share
    Novartis Pluvicto Shows rPFS Benefit In PSMA+ Prostate Cancer
    Novartis Pluvicto Shows rPFS Benefit In PSMA+ Prostate Cancer

    02 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/02/3091542/0/en/Novartis-Pluvicto-demonstrates-statistically-significant-and-clinically-meaningful-rPFS-benefit-in-patients-with-PSMA-positive-metastatic-hormone-sensitive-prostate-cancer.html

    GLOBENEWSWIRE
    02 Jun 2025
    Share Share
    FDA approve Novartis therapy Pluvicto for earlier use in Prostate Cancer
    FDA approve Novartis therapy Pluvicto for earlier use in Prostate Cancer

    28 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/28/3051533/0/en/FDA-approves-Novartis-radioligand-therapy-Pluvicto-for-earlier-use-before-chemotherapy-in-PSMA-positive-metastatic-castration-resistant-prostate-cancer.html

    GLOBENEWSWIRE
    28 Mar 2025
    Share Share
    Enforcement Report - Week of October 9, 2024
    Enforcement Report - Week of October 9, 2024

    09 Oct 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-9-2024-25441.pdf

    FDA
    09 Oct 2024
    Share Share
    Lantheus' Phase 3 Radiotherapy Results Fail To Surpass Pluvicto
    Lantheus' Phase 3 Radiotherapy Results Fail To Surpass Pluvicto

    16 Sep 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/esmo-lantheus-phase-3-radiotherapy-readout-not-enough-topple-pluvicto-say-analysts

    FIERCE BIOTECH
    16 Sep 2024
    Share Share
    Novartis gears up for key expansions of 3 cancer drugs
    Novartis gears up for key expansions of 3 cancer drugs

    24 Apr 2024

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma/novartis-dials-2024-sales-outlook-preps-key-expansions-3-cancer-drugs

    Angus Liu FIERCE PHARMA
    24 Apr 2024
    Share Share